News

Update on Monoclonal Antibody Therapies

On December 23, 2020 by Kari Everson

LeadingAge Minnesota received information this week from the Minnesota Department of Health (MDH) about the status of implementation of monoclonal antibody therapies for COVID-19, and we wanted to share the lates with members.

Emergency Use Authorization Published for Monoclonal Antibody Therapy for COVID-19

On November 11, 2020 by Kari Everson

Monoclonal antibody therapy is a COVID-19 treatment that appears to prevent the progression of COVID-19 disease, decrease the length of illness, and may prevent hospitalizations. An Emergency Use Authorization (EUA) was published today allowing the emergency use of monoclonal antibody therapy (Bamlanivimab) for adults and children with a positive COVID-19 test. Recipients must be 12 years of age or older or at least 40kg in weight. There are specific criteria for use of this therapy including:

• The recipient should have a confirmed COVID-19 infection;
• The recipient should be early in the disease progression; and
• The recipient should be symptomatic but not severely ill.